<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364988</url>
  </required_header>
  <id_info>
    <org_study_id>PLAN</org_study_id>
    <nct_id>NCT00364988</nct_id>
  </id_info>
  <brief_title>Pioglitazone and Losartan Provides Additional Renoprotection</brief_title>
  <official_title>Combination Therapy With Pioglitazone and Losartan Provides Additional Renoprotection in Subjects With Type 2 Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are
      currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or
      in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of
      proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional
      renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function</measure>
    <time_frame>12 month</time_frame>
    <description>fasting glucose, HbA 1c , Scr, 24-hour urinary protein excretion, and endogenous creatinine clearance (Ccr)</description>
  </primary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Diabetic Nephropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone+losartan</intervention_name>
    <description>Pioglitazone (30 mg/daily) losartan (100 mg daily)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan</intervention_name>
    <description>losartan (100 mg daily)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L

          -  2h plasma glucose level of 7.5-13 mmol/L

          -  serum creatinine values between 190 and 660umol/L

          -  Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours
             urinary protein concentration is ＞150mg

          -  Informed consent

        Exclusion Criteria:

          -  Type1 diabetes or nondiabetic renal disease

          -  abnormal liver function

          -  heart dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>32 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui M Jin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai No.3 People's Hospital</affiliation>
  </overall_official>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2006</study_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hui Min Jin</investigator_full_name>
    <investigator_title>Chief,department of Nephrology,shanghai No.3 people's hospital</investigator_title>
  </responsible_party>
  <keyword>pioglitazone</keyword>
  <keyword>losartan</keyword>
  <keyword>proteinuria</keyword>
  <keyword>end stage renal disease (ESRD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

